Alto Neuroscience, Inc. (NYSE:ANRO – Free Report) – Research analysts at HC Wainwright upped their Q3 2026 EPS estimates for shares of Alto Neuroscience in a research note issued to investors on Monday, August 17th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.67) per share for the quarter, up from their previous estimate of ($0.72). HC Wainwright has a “Buy” rating and a $55.00 price objective on the stock. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Alto Neuroscience’s Q4 2026 earnings at ($0.68) EPS, FY2026 earnings at ($2.80) EPS, Q1 2027 earnings at ($0.93) EPS, Q2 2027 earnings at ($0.97) EPS, Q3 2027 earnings at ($1.00) EPS, Q4 2027 earnings at ($0.96) EPS, FY2027 earnings at ($3.87) EPS, FY2028 earnings at ($4.39) EPS, FY2029 earnings at ($3.25) EPS and FY2030 earnings at ($1.29) EPS.
Several other brokerages also recently commented on ANRO. BTIG Research raised their target price on Alto Neuroscience from $28.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, August 13th. Wolfe Research assumed coverage on Alto Neuroscience in a report on Friday, May 22nd. They set an “outperform” rating for the company. Robert W. Baird lowered their target price on Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating on the stock in a research report on Monday, May 18th. Bank of America began coverage on Alto Neuroscience in a report on Tuesday, May 5th. They issued a “buy” rating and a $35.00 target price on the stock. Finally, Zacks Research downgraded shares of Alto Neuroscience from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 22nd. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $37.25.
Alto Neuroscience Trading Up 1.8%
Shares of ANRO stock opened at $34.19 on Wednesday. The company has a market cap of $1.20 billion, a P/E ratio of -14.13 and a beta of 1.06. Alto Neuroscience has a fifty-two week low of $3.32 and a fifty-two week high of $34.54. The company has a debt-to-equity ratio of 0.07, a quick ratio of 14.85 and a current ratio of 14.85. The stock has a 50 day simple moving average of $26.54 and a two-hundred day simple moving average of $23.04.
Alto Neuroscience (NYSE:ANRO – Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.65) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.08.
Hedge Funds Weigh In On Alto Neuroscience
Large investors have recently bought and sold shares of the stock. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Alto Neuroscience by 14,567.0% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 212,672 shares of the company’s stock worth $3,786,000 after buying an additional 211,222 shares during the last quarter. Jennison Associates LLC purchased a new position in Alto Neuroscience in the first quarter worth $8,687,000. Y Intercept Hong Kong Ltd purchased a new position in Alto Neuroscience in the first quarter worth $538,000. Orbimed Advisors LLC increased its position in shares of Alto Neuroscience by 34.0% during the 1st quarter. Orbimed Advisors LLC now owns 167,500 shares of the company’s stock valued at $3,765,000 after purchasing an additional 42,500 shares during the last quarter. Finally, Perceptive Advisors LLC raised its stake in shares of Alto Neuroscience by 12.6% during the 1st quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company’s stock worth $45,182,000 after purchasing an additional 225,500 shares during the period.
Key Stories Impacting Alto Neuroscience
Here are the key news stories impacting Alto Neuroscience this week:
- Positive Sentiment: HC Wainwright raised its price target for Alto Neuroscience from $50 to $55 and maintained a “Buy” rating. The new target implies substantial upside from the recently referenced $34.19 share price. Alto Neuroscience Stock Price Expected to Rise, HC Wainwright Analyst Says
- Positive Sentiment: The firm improved its EPS forecasts across multiple periods, including fiscal 2026 through fiscal 2030 and each quarter from the third quarter of 2026 through the fourth quarter of 2027. Although Alto remains expected to report losses, the revised estimates indicate smaller losses—for example, fiscal 2026 EPS improved to $(2.80) from $(2.98), fiscal 2027 to $(3.87) from $(4.39), and fiscal 2030 to $(1.29) from $(1.53). This suggests HC Wainwright sees a stronger path toward profitability and supports investor optimism.
- Neutral Sentiment: The revisions remain analyst-driven and do not represent realized earnings or a new clinical-trial result. Alto Neuroscience is still expected to post a loss, with consensus EPS at approximately $(2.71) for the current year, so future clinical, regulatory, and cash-burn developments remain important risks.
About Alto Neuroscience
Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.
Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.
Featured Stories
- Five stocks we like better than Alto Neuroscience
- Speed Sells: Cerebras Cracks the Silicon Ceiling
- Amid Legal Risks, This Company Is Still Rated a Buy
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.
